This information on this website is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
The information on this website is intended for residents outside the United States and Canada. The products discussed herein may have different labeling in different countries.
This week marks the anniversary of the tragic passing of Dr. Barry Sherman, Founder of the Apotex family of companies. Barry had the courage to support the development of Ferriprox® despite enormous obstacles. His vision, focus, and tenacity enabled Ferriprox to be used in patients worldwide, thus changing the lives of many patients around the globe. We continue to commemorate Barry’s legacy by maintaining our research into hematologic conditions of iron overload and by studying deferiprone’s potential benefits in neurodegenerative disorders, where iron may play a role.
Driving Innovation
ApoPharma Inc. evolved from the Innovative Drug Division of the Apotex family of companies. Our research focus is on the use of medicines to treat disorders caused or worsened by excessive iron or faulty processing of iron in cells in the body. These disorders include both generalized iron overload, which affects patients who must undergo repeated blood transfusions, and localized iron dysregulation in the brain, which underlies a number of neurological disorders such as pantothenate kinase-associated neurodegeneration and Parkinson's disease.
ApoPharma Inc. is focused on the development of products that can help people who have debilitating and life-threatening conditions that are caused by or worsened by iron.